Training program for researchers in kidney, urologic, and blood diseases
Official title: The Philadelphia Program for Mentored Research Training in Kidney, Urologic, and Hematologic Diseases (PERFORM-KUH U2C/Tl1)
Funded at University of Pennsylvania · NIH-11168979 · Data updated 2026-11-12
This program is designed to help people training in kidney, urologic, and blood diseases become better researchers by offering mentorship, resources, and support to boost their skills and career opportunities.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $441,796 |
| NIH project number | 5U2CDK136784-02 |
| Project ID | NIH-11168979 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this program are early-career researchers and trainees interested in pursuing careers in kidney, urologic, and hematologic research.
✕Less likely to help
Patients who are not involved in research or do not have an interest in pursuing a career in these medical fields may not benefit from this program.
What this research studies
This program aims to enhance the skills and competitiveness of trainees focusing on kidney, urologic, and hematologic diseases. It provides mentorship and professional development resources, helping participants improve their research capabilities, funding applications, and communication skills. The program also develops tailored curricula to address the specific needs of trainees in these fields, fostering a supportive environment for career advancement. By leveraging the strengths of multiple academic institutions in Philadelphia, it aims to create a collaborative network for aspiring researchers.
Why it matters
Potential benefit: If successful, this program could lead to a new generation of skilled researchers who can significantly advance the understanding and treatment of kidney, urologic, and blood diseases.
How similar studies have gone: Similar programs have shown success in enhancing research training and mentorship in various medical fields, indicating a strong potential for positive outcomes in this initiative.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Holzman, Lawrence B. — University of Pennsylvania
- Study coordinator: Holzman, Lawrence B.
Related research
Other NIH-funded projects on the same topics.
-
First-in-class complement inhibitor for blood diseases that damage red blood cells
A new, targeted therapy being developed to help people with blood diseases like PNH and AIHA by blocking the immune system’s complement attack on red blood cells.
-
Mentored research training and professional development for kidney, urologic, and hematologic diseases
A program to help trainees in Philadelphia-area kidney, urologic, and blood disease research build skills, get mentoring, and prepare for future scientific careers.
-
A new targeted drug to block harmful complement activity in blood disorders
A novel nanobody drug designed to block the complement system to help people with PNH or autoimmune hemolytic anemia.
-
Creating a new treatment to block harmful immune responses in blood diseases
This study is working on a new treatment to help people with blood disorders like PNH and AIHA by creating special therapies that can stop the body from destroying red blood cells too quickly, aiming to offer better options than what’s currently available.
-
Gene editing in bone marrow to treat blood disorders
This study is exploring a new way to use gene editing to treat blood disorders like sickle cell disease and β-thalassemia by making changes directly in the bone marrow, which could be safer and cheaper than current methods.
-
Romiplostim to help platelets grow after donor stem cell transplant
This phase II trial tests whether weekly romiplostim helps patients over 18 who receive a haploidentical or fully matched unrelated donor stem cell transplant to engraft platelets faster than best supportive care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.